Nav: Home

Research on the impact of ACE-i and ARBs for patients with COVID-19 continues to evolve

September 10, 2020

DALLAS, Sept. 10, 2020 -- Reducing or eliminating high blood pressure medications if blood pressure becomes hypotensive, falling below 120/70 mm Hg, could prevent acute kidney injury and death in COVID-19 patients, according to new research to be presented Sept. 10-13, 2020, at the virtual American Heart Association's Hypertension 2020 Scientific Sessions. The meeting is a premier global exchange for clinical and basic researchers focusing on recent advances in hypertension research.

Early in the COVID-19 pandemic, the American Heart Association issued a joint statement with the Heart Failure Society of America and the American College of Cardiology to address the use of ACE-i and ARB medications among patients at risk for developing COVID-19. Recommendations called for the continuation of ACE-i or ARB medications among patients already taking them for indications such as heart failure, hypertension or ischemic heart disease. Cardiovascular disease patients who are diagnosed with COVID-19 should be fully evaluated before adding or removing any treatments, and any changes to their treatment should be based on the latest scientific evidence and shared-decision making with their physician and health care team.

"While we continue to learn more about the complex impact of COVID-19 every day, we know that people with cardiovascular disease and/or hypertension are at much higher risk for serious complications including death from COVID-19," said Mariell Jessup, M.D., FAHA, chief science and medical officer of the American Heart Association. "We continue to monitor and review the latest research, and we strongly recommend all physicians to consider the individual needs of each patient before making any changes to ACE-i or ARB treatment regimens. The latest research findings do suggest, however, that these medications should be discontinued in patients who develop hypotension in order to avoid severe kidney damage."

"Acute kidney injury, also known as acute kidney failure, is a serious COVID-19 complication, and many people with the virus are at risk," according to study author Paolo Manunta, M.D., Ph.D., chair of nephrology at San Raffaele University in Milan, Italy.

To determine which COVID-19 patients are most at risk for kidney damage (#P145), Manunta and colleagues studied 392 COVID-19 patients hospitalized between March 2 and April 25, 2020, treated at one center in Italy (#P145).

They found:

Nearly 60% had a history of hypertension, making it the most common co-occurring health issue in these patients.

More than 86% of patients with high blood pressure were taking anti-hypertensive medications daily.

Overall, 6.2% of the patients came into the emergency department with acute kidney injury -- kidney function and hypertension were the main determinants of whether a person had acute kidney injury.

Having a history of hypertension increased the risk of acute kidney injury by about five-fold.

Patients presenting to the emergency department who had severe hypotension, meaning blood pressure lower than 95/50 mm Hg, were nine times more likely to have acute kidney injury; while those who had mild hypotension, blood pressure lower than 120/70 mm Hg but not in the severe range, were four times more likely to have acute kidney injury.

COVID-19 patients who were more likely to develop acute kidney injury while hospitalized were elderly, hypertensive or had severe respiratory distress.

However, overall, in-hospital death was twice as likely in patients with mild hypotension when they arrived at the emergency department, regardless of age, other diseases and COVID-19 severity.

"Our study suggests low blood pressure in a person with a history of high blood pressure is an important and independent signal that someone with COVID-19 is developing or has acute kidney injury," Manunta said. "This also suggests that people with high blood pressure should carefully monitor it at home, and their kidney function should be measured when they're first diagnosed with COVID-19. If they or their doctors notice blood pressure levels going down to the hypotensive range, their doctors may consider reducing or stopping their blood pressure medications to prevent kidney damage and possibly even death."

Study limitations include its relatively small sample size in a single-center population and the brevity of the study period.

Co-authors are Chiara Livia Lanzani, M.D.; Marco Simonini, M.D; Elisabetta Messaggio, B.S.; Teresa Arcidiacono, M.D.; Paolo Betti, M.D.; Romina Bucci, M.D.; Fontana Simonet, M.D.; Caterina Conte, M.D.; Giuseppe Vezzoli, M.D.; Patrizia Rovere-Querini, M.D., Ph.D.; Conte Caterina M.D.; and Ciceri Fabio M.D., Ph.D. IRCCS San Raffaele funded this study.

Pre-existing high blood pressure common in those hospitalized for COVID-19 (#P135)

In another study presented at the meeting, researchers confirmed previous findings that hypertension is the most common co-existing disease among hospitalized COVID-19 patients.

They analyzed 22 studies from eight countries with more than 11,000 total, hospitalized COVID-19 patients. Researchers found 42% of patients had hypertension, followed by diabetes mellitus, which affected 23% of patients.

Hypertension, alone, was associated with a higher likelihood of death. Surprisingly, hypertension was notably more common than the lung disease chronic obstructive pulmonary disease (COPD) among hospitalized COVID-19 patients, according to the researchers.

"More randomized studies are needed to assess the effect of hypertension on mortality in COVID-19 patients," said researchers in the abstract.

Authors are Vikramaditya Reddy Samala Venkata, M.D.; Rahul Gupta, M.D.; and Surya Kiran Aedma, M.D.

Common blood pressure-lowering drugs may pose increased risks for COVID-19 patients (#P144)

In a third study from the meeting, researchers at the University of Miami/JFK Medical Center in Atlantis, Florida, studied hospitalized COVID-19 patients to determine the effects of taking the blood pressure-lowering prescriptions angiotensin-converting enzyme inhibitors (ACE-i) and/or angiotensin receptor blockers (ARBs). They found that patients taking the medications were more likely to die than those who were not taking them.

In the single-center, retrospective study, researchers studied 172 patients hospitalized for COVID-19 between March and May 2020. They found 33% of patients taking one or both of the anti-hypertensive medications (ACE-i, ARBs) died in the hospital, versus 13% of those not taking either of the medications. Admission to the intensive care unit was also higher -- at 28% among those on the medications versus 13% of patients not taking ACE-i and/or ARB medications.

The higher risk of death among patients taking the antihypertensive medications could be because people prescribed those medications tend to be older and are more likely to have diabetes mellitus and hypertension, researchers noted in the abstract.
-end-
Study authors are Baher Al-Abbasi, M.D.; Nakeya Dewaswala, M.D.; Fergie Ramos, M.D.; Ahmed Abdallah, M.D.; Pedro Torres, M.D.; Kai Chen, M.D.; Mohamed Abdul Qader, M.D.; Samar Aboulenain, M.D.; Karolina Dziadkowiec, M.D.; Jesus Pino, M.D.; and Robert D Chait, M.D.

Additional Resources:

Available multimedia is on right column of release link https://newsroom.heart.org/news/research-on-the-impact-of-ace-i-and-arbs-for-patients-with-covid-19-continues-to-evolve?preview=e36be23f32814f82b6243900cc3ec376

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

American Heart Association

Related Heart Failure Articles:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication
Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.
Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.
Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population
Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.
Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.
Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.
Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.
How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.
Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.
More Heart Failure News and Heart Failure Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.